Physician profile
Charles P Lichty
NPI 1487627766
$4,559.30
in general payments reported to CMS, 2019-2025
27 companies · $678 in 2025
The $678 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $612 · 2021: $440 · 2022: $709 · 2023: $621 · 2024: $812 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.78 |
| Education | $109.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,255.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $674.27 | 2019-2025 | |
| Abbvie INC. | $398.34 | 2021-2025 | |
| Lilly USA, LLC | $370.84 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $253.97 | 2019-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $219.76 | 2019-2025 | Veozah, Cresemba |
| Glaxosmithkline, LLC. | $197.95 | 2019-2025 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.16 | 2019-2022 | |
| Amgen INC. | $151.59 | 2020-2025 | Repatha, Repatha, Otezla |
| La Jolla Pharmaceutical Company | $113.65 | 2024-2025 | Xacduro, Zevtera |
| Melinta Therapeutics, LLC | $106.51 | 2021-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Novartis Pharmaceuticals Corporation | $97.81 | 2022-2025 | |
| Amarin Pharma, INC. | $82.26 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $67.15 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $60.01 | 2022-2024 | Eliquis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $49.36 | 2021-2025 | Zerbaxa, Dificid |
| Allergan, INC. | $40.48 | 2020 | |
| Dexcom, INC. | $38.62 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $37.16 | 2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $31.17 | 2025 | Cologuard Collection Kit |
| Endogastric Solutions, INC | $30.00 | 2024 | Esophyx |
| Sumitomo Pharma America, INC. | $28.33 | 2023 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $21.38 | 2019 | |
| Horizon Therapeutics Plc | $20.58 | 2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $19.46 | 2019 | |
| Pulmonx Corporation | $16.26 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Daiichi Sankyo INC. | $14.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lichty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.